Akums Drugs and Subsidiary Face Over ₹133 Crore Tax Demand

Akums Drugs and Pharmaceuticals Ltd. and its subsidiary Akumentis Healthcare Ltd. (AHL) have received assessment orders from the Income Tax Department, covering the period from April 1, 2018, to March 12, 2025.

Akums Drugs faces a demand of ₹60.09 crore, while AHL has been issued a demand for ₹73.66 crore. Both figures result from expenditures deemed disallowed during the tax assessment.

Tax Demands Issued

Akums Drugs and Pharmaceuticals Ltd. and its subsidiary, Akumentis Healthcare Ltd., have been notified of tax assessment orders by the Income Tax Department. The total demand against Akums Drugs is ₹60,09,22,342, and against AHL, it is ₹73,66,10,238. These assessments cover a block period from April 1, 2018, to March 12, 2025.

Companies Plan to Appeal

These substantial tax demands could affect the companies' financial health if they are not resolved. However, Akums Drugs and AHL intend to appeal the orders, indicating their belief that the demands are not justified. The outcome of these appeals will be closely watched, as a successful challenge would eliminate the financial burden.

Tax Assessment Details

The tax assessment orders were issued on May 20, 2026, for Akums Drugs and on May 19, 2026, for AHL. The companies received these notices on May 20, 2026. The assessment review covered expenditures from a seven-year span.

Creating a Contingent Liability

The issuance of these tax demands creates a contingent liability for the companies. Akums Drugs and AHL will now proceed with the appeals process to contest the demands.

Potential Financial Risks

The primary risk lies in the financial implications should the appeals fail. If the tax demands are upheld, the combined ₹133.75 crore would need to be paid, potentially impacting the companies' liquidity and profitability.

Next Steps for Investors

Investors are advised to monitor the progress of Akums Drugs and Akumentis Healthcare's appeals against these Income Tax assessment orders. Any developments regarding the appeals' outcomes will be significant.